Citalopram treatment of paroxetine-intolerant depressed patients

Depression and Anxiety

Volumn 16, Issue 3, 2002, Pages 128-133

  Thase, Michael E ^a   Ferguson, James M ^b   Lydiard, R Bruce ^c   Wilcox, Charles S ^d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Pharmacology Research Corporation   (United States)

^c Southeast Health Consultants LLC   (United States)

^d Pharmacology Research Institute   (United States)

Author keywords

Antidepressant; Citalopram; Paroxetine; Side effects; Tolerability

Indexed keywords

CITALOPRAM; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANORGASMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; EJACULATION DISORDER; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SYMPTOM; XEROSTOMIA;

ADULT; ANXIETY DISORDERS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DRUG TOLERANCE; FEMALE; HUMANS; MALE; PAROXETINE; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 0036431350     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/da.10055     Document Type: Article

References (34)

1. Baumann P. 1996. Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol 11 (suppl 1):5-11.
2. Bech P, Cialdella P. 1992. Citalopram in depression - Meta-analysis of intended and unintended effects. Int Clin Psychopharmacol 6 (Suppl 5):45-54.
3. Bech AT, Ward CH, Mendelson M. 1961. An inventory for measuring depression. Arch Gen Psychiatry 4:561-571.
4. Brown WA, Harrison W. 1995. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 56:30-34.
5. Charney DS, Berman RM, Miller H. 1998. Treatment of depression. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press. p 705-731.
6. DeVane CL. 1995. Comparative safety and tolerability of selective serotonin reuptake inhibitors. Hum Psychopharmacol 10:S185-S193.
7. Edwards JG, Anderson I. 1999. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57:507-533.
8. Ferguson JM, Shrivastava RK, Stahl SM, Hartford JT, Borian F, Ieni J, McQuade RD,Jody D. 2001. Reemergence of sexual dysfunction in patients with major depressive disorder: Double blind comparison of nefazodone and sertraline. J Clin Psychiatry 62:24-29.
9. Fredman SJ, Fava M, Kienke AS, White CN, Nierenberg AA, Rosenbaum JF. 2000. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: A survey of current "next-step" practices. J Clin Psychiatry 61:403-408.
10. Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: Superintendent of Documents, U.S. Government Printing Office, U.S. Department of Health, Education, and Welfare publication no. 76-338.
11. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
12. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
13. Heinrichs DW, Hanlon TE, Carpenter WT Jr (1984) The quality of life scale: An instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10:388-398.
14. Hyttel J. 1994. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9:19-26.
15. Jefferson JW, Greist JH. 2000. A double-blind comparison of citalopram and paroxetine in the treatment of patients with depression and anxiety. Presented at: The Annual Meeting of the American College of Neuropsychopharmaocology; Dec. 10-14, San Juan, Puerto Rico. Abstract NR119.
16. Joffe RT, Levitt AJ, Sokolov ST, Young LT. 1996. Response to an open trial of a second SSRI in major depression [see comment]. J Clin Psychiatry 57:114-115.
17. Kasper S. 1997. Mirtazapine: A novel antidepressant combining clinical efficacy and improved tolerability. Prim Care Psychiatry 3:7-16.
18. Montgomery SA, Djarv L. 1996. The antidepressant efficacy of citalopram. Int Clin Psychopharmacol 11 (suppl 1):29-33.
19. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D. 1994. Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates. Int Clin Psychopharmacol 9:47-53.
20. Mucci M. 1997. Reboxetine: A review of antidepressant tolerability. J Psychopharmacol 1:S33-S37.
21. Posternak MA, Zimmerman M. 2001. Switching versus augmentation: A prospective, naturalistic comparison in depressed, treatment-resistant patients. J Clin Psychiatry 62:135-142.
22. Preskorn SH. 1994. Antidepressant drug selection: Criteria and options. J Clin Psychiatry 55 (Suppl A):6-22; discussion 23-24, 98-100.
23. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. 1998. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial [see comments]. Biol Psychiatry 44:77-87.
24. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, Mason J. 1993. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability [see comments]. Br Med J 306:683-687.
25. Sussman N, Ginsberg D. 1998. Weight gain associated with SSRIs. Prim Psychiatry January:28-41.
26. Thase ME. 1999. How should efficacy be evaluated in randomized clinical trials of treatments for depression? J Clin Psychiatry 60 (suppl 4):23-31.
27. Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG. 1997. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 58:16-21.
28. Thase ME, Feighner JP, Lydiard RB. 2001. Citalopram treatment for fluoxetine nonresponders. J Clin Psychiatry 62:683-687.
29. Thase ME, Kupfer DJ. 1996. Recent developments in the pharmacotherapy of mood disorders. J Consult Clin Psychol 64:646-659.
30. Thase ME, Londborg P, Calabrese JR. Citalopram treatment of depressed patients discontinued from fluoxetine because of adverse events. Presented at the American College of Neuropsychopharmacology Annual Meeting, December 12-16, 1999, Acapulco, Mexico.
31. Thase ME, Rush AJ. 1997. When at first you don't succeed... Sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58 (Suppl 3):23-29.
32. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B. 1998. Effect of SSRI antidepressants on ejaculation: A double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol 18:274-281.
33. Waldinger MD, Zwinderman AH, Olivier B. 2001. SSRIs and ejaculation: A double-blind, randomized, fixed-dose study with paroxetine and citalopram. J Clin Psychopharmacol 21:556-560.
34. Zarate CA, Kando JC, Tohen M, Weiss MK, Cole JO. 1996. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry 57:67-71.